GO:0048662 negative regulation of smooth muscle cell proliferation: Vascular Remodeling, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048662 describes any biological process that stops, prevents, or reduces the rate or extent of smooth muscle cell proliferation.
• Loss of negative regulation of smooth muscle cell proliferation drives vascular remodeling diseases such as pulmonary arterial hypertension and atherosclerosis.
• Key negative regulators include DUSP5, which dephosphorylates ERK1/2 to suppress proliferation and pulmonary hypertension, and calreticulin, which inhibits bronchial smooth muscle cell proliferation.
• Fibroblast-derived signals such as Smad7 induction protect the pressure-overloaded heart by modulating remodeling, while PDZ-binding kinase promotes vascular remodeling when unchecked.
• microRNAs such as miR-342-5p regulate smooth muscle phenotypic transition through Notch signaling and FOXO3, and TWIST1 domains control smooth muscle cell phenotype.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to causally test candidate negative regulators in smooth muscle proliferation.
Description
Smooth muscle cells (SMCs) are contractile cells that line hollow organs and blood vessels, and their proliferation is a tightly controlled process essential for vascular homeostasis and tissue repair. The Gene Ontology term GO:0048662, negative regulation of smooth muscle cell proliferation, captures the biological processes that stop, prevent, or reduce the rate or extent of SMC proliferation. Dysregulation of this process is a hallmark of vascular proliferative diseases, including pulmonary arterial hypertension, atherosclerosis, and restenosis after angioplasty. Understanding the molecular brakes on SMC proliferation is therefore critical for identifying therapeutic targets and biomarkers. Research over the past two decades has identified diverse negative regulators of SMC proliferation, ranging from dual-specificity phosphatases such as DUSP5 to calcium-binding proteins like calreticulin and microRNAs such as miR-342-5p. These regulators act through distinct signaling nodes, including MAPK/ERK, Notch, and FOXO3 pathways. In parallel, fibroblast-derived factors such as Smad7 modulate the remodeling response in the pressure-overloaded heart, highlighting the cross-talk between cell types in controlling SMC proliferation. For researchers, GO:0048662 provides a structured framework to annotate and interpret high-throughput data, from RNA-seq to CRISPR screens. This article synthesizes authoritative QuickGO definitions and verified PubMed literature to deliver a publication-ready overview of the genes, mechanisms, disease links, and experimental models relevant to negative regulation of smooth muscle cell proliferation.
negative regulation of smooth muscle cell proliferation At A Glance
| GO ID | GO:0048662 |
|---|---|
| GO term | negative regulation of smooth muscle cell proliferation |
| Ontology | biological_process |
| Synonym | down regulation of smooth muscle cell proliferation; down-regulation of smooth muscle cell proliferation; downregulation of smooth muscle cell proliferation; inhibition of smooth muscle cell proliferation; negative regulation of SMC proliferation |
| Major function | Suppresses the rate or extent of smooth muscle cell proliferation to maintain vascular and organ homeostasis |
| Related diseases | Pulmonary arterial hypertension, right ventricular hypertrophy, atherosclerosis, restenosis |
| Key regulators | DUSP5, calreticulin, miR-342-5p, Smad7, PDZ-binding kinase, TWIST1 |
| Experimental models | CRISPR knockout, point mutation, knock-in, overexpression in SMC lines and animal models |
What Is GO:0048662?
GO:0048662, negative regulation of smooth muscle cell proliferation, is defined as any process that stops, prevents, or reduces the rate or extent of smooth muscle cell proliferation. It is a biological_process term in the Gene Ontology, with synonyms including down regulation of smooth muscle cell proliferation, inhibition of smooth muscle cell proliferation, and negative regulation of SMC proliferation. This term encompasses signaling events, transcriptional programs, and post-transcriptional mechanisms that suppress the entry, progression, or completion of the smooth muscle cell cycle.
Why Is negative regulation of smooth muscle cell proliferation Important in Cell Biology?
Negative regulation of smooth muscle cell proliferation is a central protective mechanism against vascular occlusive diseases. When this brake fails, SMCs proliferate excessively, leading to neointimal hyperplasia, pulmonary arterial hypertension, and right ventricular hypertrophy. Conversely, enhancing negative regulators such as DUSP5 or calreticulin can suppress pathological remodeling. Thus, GO:0048662 is a high-value target space for therapeutic development and for interpreting genomic and pharmacologic data in cardiovascular research.
• Prevents pathological vascular remodeling in pulmonary arterial hypertension.
• Suppresses neointimal hyperplasia and restenosis after vascular injury.
• Protects against right ventricular hypertrophy secondary to pulmonary hypertension.
• Modulates airway remodeling in asthma through bronchial SMC proliferation control.
• Coordinates fibroblast-myocyte cross-talk in the pressure-overloaded heart.
• Provides mechanistic biomarkers for cardiovascular risk stratification.
• Serves as a therapeutic target for small molecules and biologics.
• Enables functional annotation of GWAS loci in vascular disease.
• Guides CRISPR screen design for anti-proliferative drug discovery.
• Links microRNA networks to smooth muscle phenotypic switching.
What Happens During negative regulation of smooth muscle cell proliferation?
Initiation of anti-proliferative signaling
In simple terms: A brake signal is applied to stop smooth muscle cells from dividing.
Negative regulation begins when extracellular or intracellular cues activate anti-proliferative pathways. For example, DUSP5 is induced and acts as a nuclear brake on ERK1/2 signaling, reducing SMC proliferation and suppressing pulmonary hypertension. Similarly, calreticulin acts as a negative regulator of bronchial smooth muscle cell proliferation, providing a brake in airway remodeling. Fibroblast-derived Smad7 induction in the pressure-overloaded heart also initiates protective remodeling signals.
Signal transduction and kinase deactivation
In simple terms: The brake signal turns off growth-promoting kinases.
A key step is the deactivation of pro-proliferative kinases. DUSP5 dephosphorylates ERK1/2, directly inhibiting SMC proliferation. PDZ-binding kinase (PBK) is a novel regulator of vascular remodeling in pulmonary arterial hypertension, and its inhibition is associated with reduced proliferative signaling. The balance between kinases and phosphatases thus determines whether SMCs remain quiescent or proliferate.
Transcriptional and post-transcriptional control
In simple terms: Gene expression programs are rewired to keep cells from dividing.
Transcriptional regulators such as TWIST1 domains control smooth muscle cell phenotype, and functional analysis of TWIST1 domains regulates SMC phenotype. Post-transcriptionally, miR-342-5p promotes vascular smooth muscle cell phenotypic transition through negative-feedback regulation of Notch signaling via targeting FOXO3. These layers ensure robust suppression of proliferation under physiological conditions.
Phenotypic transition and quiescence
In simple terms: Cells switch from a dividing state to a quiet, contractile state.
Successful negative regulation results in a phenotypic transition from synthetic, proliferative SMCs to contractile, quiescent SMCs. miR-342-5p and Notch/FOXO3 signaling contribute to this transition. TWIST1 domain functions further modulate the phenotypic state. This step is critical for restoring vascular homeostasis and preventing occlusive disease.
Cross-talk with fibroblasts and the microenvironment
In simple terms: Other cells in the tissue help apply the brake.
Fibroblast Smad7 induction protects the remodeling pressure-overloaded heart, demonstrating that negative regulation of SMC proliferation is not cell-autonomous but involves microenvironmental cross-talk. Autophagic degradation of SQSTM1 enables fibroblast activation to accelerate wound healing, illustrating how stromal cells influence proliferative outcomes. Heparan sulfate 6-O-endosulfatase1 also regulates vascular SMC proliferation, migration, and death, linking matrix remodeling to proliferative control.
Key Genes Involved in GO:0048662 negative regulation of smooth muscle cell proliferation
The following genes and proteins have been experimentally implicated in negative regulation of smooth muscle cell proliferation, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DUSP5 | Dephosphorylates ERK1/2 to inhibit SMC proliferation | Suppresses pulmonary hypertension and right ventricular hypertrophy |
| CALR | Calreticulin acts as a negative regulator of bronchial SMC proliferation | Airway remodeling and asthma research |
| MIR342-5P | Regulates SMC phenotypic transition via Notch/FOXO3 | microRNA-based modulation of vascular phenotype |
| SMAD7 | Fibroblast Smad7 induction protects pressure-overloaded heart | Cardiac remodeling and fibrosis research |
| PBK | PDZ-binding kinase regulates vascular remodeling in PAH | Therapeutic target in pulmonary arterial hypertension |
| TWIST1 | Domain-specific regulation of SMC phenotype | Transcription factor structure-function studies |
| SULF1 | Heparan sulfate 6-O-endosulfatase1 regulates SMC proliferation, migration, death | Matrix-remodeling and vascular biology |
| SQSTM1 | Autophagic degradation enables fibroblast activation | Wound healing and stromal cross-talk |
| FOXO3 | Target of miR-342-5p in Notch feedback | Phenotypic switching and proliferation control |
| NOTCH1 | Notch signaling modulated by miR-342-5p | Vascular SMC fate decisions |
| ERK1/2 | Downstream targets of DUSP5 | MAPK pathway readout in proliferation assays |
| ACTA2 | Contractile marker of quiescent SMCs | Phenotype validation in CRISPR models |
| MYH11 | Contractile marker of differentiated SMCs | Phenotype validation in CRISPR models |
| PCNA | Proliferation marker | Quantification of SMC proliferation |
| MKI67 | Proliferation marker | Quantification of SMC proliferation |
| CDKN1A | Cell cycle inhibitor | Readout of anti-proliferative signaling |
| CDKN1B | Cell cycle inhibitor | Readout of anti-proliferative signaling |
How Is negative regulation of smooth muscle cell proliferation Regulated?
Negative regulation of smooth muscle cell proliferation is controlled at multiple levels. DUSP5-mediated inhibition of ERK1/2 suppresses pulmonary hypertension and right ventricular hypertrophy, establishing MAPK phosphatase activity as a central regulatory node. PDZ-binding kinase (PBK) is a novel regulator of vascular remodeling in pulmonary arterial hypertension, indicating kinase-dependent control. Fibroblast Smad7 induction protects the remodeling pressure-overloaded heart, showing that TGF-beta/Smad signaling in the microenvironment regulates SMC proliferation. Post-transcriptional regulation by miR-342-5p through Notch signaling and FOXO3 provides a microRNA-based feedback loop. TWIST1 domain functions further modulate SMC phenotype, adding transcriptional control. Heparan sulfate 6-O-endosulfatase1 regulates SMC proliferation, migration, and death, linking extracellular matrix remodeling to proliferative control.
negative regulation of smooth muscle cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DUSP5 | Pulmonary hypertension and right ventricular hypertrophy | SMC-specific knockout and overexpression in hypoxia models |
| PBK | Pulmonary arterial hypertension | Kinase-dead knock-in and pharmacological inhibition |
| CALR | Airway remodeling in asthma | Bronchial SMC overexpression and knockdown |
| SMAD7 | Pressure-overloaded heart remodeling | Fibroblast-specific knockout and knock-in |
| MIR342-5P | Vascular SMC phenotypic transition | miRNA mimic/inhibitor and CRISPR knockout |
Pulmonary arterial hypertension and right ventricular hypertrophy
Loss of negative regulation of smooth muscle cell proliferation contributes to pulmonary arterial hypertension and right ventricular hypertrophy. DUSP5-mediated inhibition of SMC proliferation suppresses pulmonary hypertension and right ventricular hypertrophy, demonstrating that restoring this brake is protective. PDZ-binding kinase is a novel regulator of vascular remodeling in pulmonary arterial hypertension, and its activity is associated with pathological remodeling.
Cardiac remodeling and pressure overload
Fibroblast Smad7 induction protects the remodeling pressure-overloaded heart, indicating that negative regulation of SMC proliferation is part of a broader protective remodeling program. Autophagic degradation of SQSTM1 enables fibroblast activation to accelerate wound healing, highlighting the role of stromal cells in modulating proliferative responses.
Airway remodeling and asthma
Calreticulin is a negative regulator of bronchial smooth muscle cell proliferation, linking GO:0048662 to airway remodeling in asthma. This suggests that enhancing calreticulin function could reduce bronchial SMC hyperplasia in chronic airway diseases.
Vascular injury and restenosis
Heparan sulfate 6-O-endosulfatase1 regulates vascular smooth muscle cell proliferation, migration, and death, implicating matrix-remodeling enzymes in restenosis after vascular injury. miR-342-5p promotes vascular smooth muscle cell phenotypic transition through negative-feedback regulation of Notch signaling via targeting FOXO3, providing a microRNA-based mechanism relevant to restenosis.
From negative regulation of smooth muscle cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is DUSP5 causally required to suppress SMC proliferation? | DUSP5 knockout and overexpression in SMC lines and mouse models |
| Does PBK kinase activity drive vascular remodeling? | PBK point-mutation (kinase-dead) knock-in |
| Does calreticulin inhibit bronchial SMC proliferation? | CALR overexpression and knockout in bronchial SMC |
| How does miR-342-5p regulate Notch/FOXO3? | miR-342-5p knockout and FOXO3 knock-in reporter |
| What is the role of TWIST1 domains in SMC phenotype? | Domain-specific TWIST1 knock-in and deletion |
| Does fibroblast Smad7 protect against pressure overload? | Fibroblast-specific Smad7 knockout and overexpression |
How to Study the negative regulation of smooth muscle cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| EdU/BrdU incorporation | DNA synthesis and proliferation | SMC proliferation quantification |
| PCNA/MKI67 immunostaining | Proliferating cell fraction | Tissue and culture proliferation |
| Western blot for phospho-ERK1/2 | MAPK pathway activity | DUSP5 functional readout |
| RNA-seq | Transcriptional programs | Phenotype and pathway discovery |
| microRNA profiling | Post-transcriptional regulators | miR-342-5p discovery |
| Kinase activity assay | PBK catalytic activity | Vascular remodeling studies |
| TGF-beta/Smad reporter | Smad7 signaling | Cardiac remodeling research |
| Hypoxia and pressure-overload models | In vivo remodeling | Pulmonary hypertension and heart failure |
Proliferation assays
Quantifying SMC proliferation is the primary readout for GO:0048662. BrdU incorporation, EdU staining, and PCNA/MKI67 immunostaining are used to measure DNA synthesis and cell cycle entry. These assays are applied to DUSP5 knockout and overexpression models to establish causality.
Transcriptomic and microRNA profiling
RNA-seq and microRNA profiling identify transcriptional programs and post-transcriptional regulators of SMC proliferation. miR-342-5p was identified as a regulator of SMC phenotypic transition through Notch signaling and FOXO3. TWIST1 domain functions were dissected using transcriptomic readouts.
Signaling pathway analysis
Western blotting and phospho-specific antibodies measure ERK1/2 phosphorylation status to assess DUSP5 activity. Kinase activity assays for PBK evaluate its role in vascular remodeling. Smad7 induction is monitored by TGF-beta/Smad reporter assays.
In vivo remodeling models
Animal models of pulmonary hypertension, pressure overload, and vascular injury are used to test whether negative regulators of SMC proliferation protect against disease. DUSP5, PBK, and Smad7 have been evaluated in such models. Bronchial SMC proliferation is studied in asthma models.
How CRISPR Can Be Used to Study GO:0048662 negative regulation of smooth muscle cell proliferation
Knockout
CRISPR knockout of candidate negative regulators such as DUSP5, CALR, or SMAD7 enables loss-of-function studies to test whether they are required to suppress SMC proliferation. Knockout SMCs can be challenged with proliferative stimuli to measure EdU incorporation and ERK1/2 phosphorylation.
Point Mutation
Point mutation knock-in can dissect catalytic residues or phospho-sites. For example, kinase-dead PBK point mutants test whether PBK catalytic activity is required for vascular remodeling. Similarly, DUSP5 catalytic mutants can separate phosphatase-dependent from scaffold functions.
Knock-in
Knock-in of reporters or tagged alleles allows real-time monitoring of negative regulators. FOXO3 knock-in reporters can track miR-342-5p-mediated regulation of Notch signaling. TWIST1 domain knock-in models dissect structure-function relationships in SMC phenotype control.
Overexpression
CRISPR activation or lentiviral overexpression of DUSP5, CALR, or SMAD7 tests sufficiency in suppressing SMC proliferation. Overexpression models are valuable for validating therapeutic candidates that enhance GO:0048662.
How EDITGENE Supports negative regulation of smooth muscle cell proliferation Research
Researchers studying negative regulation of smooth muscle cell proliferation-related genes often need to determine whether a candidate gene is causally involved in suppressing SMC proliferation or is merely a correlative marker. EDITGENE provides end-to-end CRISPR services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support, enabling rigorous functional validation of GO:0048662 regulators.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of smooth muscle cell proliferation research.
Frequently Asked Questions About negative regulation of smooth muscle cell proliferation
What is GO:0048662?
GO:0048662 is the Gene Ontology term for negative regulation of smooth muscle cell proliferation, defined as any process that stops, prevents, or reduces the rate or extent of smooth muscle cell proliferation.
What genes are involved in negative regulation of smooth muscle cell proliferation?
Key genes include DUSP5, CALR, SMAD7, PBK, TWIST1, SULF1, SQSTM1, FOXO3, and MIR342-5P, based on verified PubMed studies.
How does DUSP5 inhibit smooth muscle cell proliferation?
DUSP5 dephosphorylates ERK1/2, thereby suppressing SMC proliferation and protecting against pulmonary hypertension and right ventricular hypertrophy.
What diseases are linked to loss of negative regulation of smooth muscle cell proliferation?
Pulmonary arterial hypertension, right ventricular hypertrophy, atherosclerosis, restenosis, and airway remodeling in asthma are linked to impaired negative regulation.
What is the role of calreticulin in smooth muscle cell proliferation?
Calreticulin acts as a negative regulator of bronchial smooth muscle cell proliferation, suggesting a protective role in airway remodeling.
How does miR-342-5p regulate smooth muscle cell phenotype?
miR-342-5p promotes vascular smooth muscle cell phenotypic transition through negative-feedback regulation of Notch signaling via targeting FOXO3.
What experimental models are used to study GO:0048662?
CRISPR knockout, point mutation, knock-in, and overexpression models in SMC lines and animal models of pulmonary hypertension and cardiac remodeling are commonly used.
What is the role of Smad7 in cardiac remodeling?
Fibroblast Smad7 induction protects the remodeling pressure-overloaded heart, indicating a protective role in cardiac remodeling.
How is PDZ-binding kinase involved in pulmonary arterial hypertension?
PDZ-binding kinase is a novel regulator of vascular remodeling in pulmonary arterial hypertension, and its activity is associated with pathological remodeling.
What methods measure smooth muscle cell proliferation?
EdU/BrdU incorporation, PCNA/MKI67 immunostaining, and phospho-ERK1/2 Western blotting are standard methods to measure SMC proliferation and signaling.
Conclusion
GO:0048662, negative regulation of smooth muscle cell proliferation, is a critical biological process that protects against vascular remodeling diseases such as pulmonary arterial hypertension, right ventricular hypertrophy, and restenosis. Key regulators including DUSP5, calreticulin, Smad7, PBK, TWIST1, and miR-342-5p act through MAPK, TGF-beta/Smad, and Notch/FOXO3 pathways to suppress SMC proliferation. CRISPR-based knockout, point mutation, knock-in, and overexpression models are indispensable for causally validating these regulators and for discovering new therapeutic targets. EDITGENE offers comprehensive CRISPR services and bioinformatics support to accelerate research on negative regulation of smooth muscle cell proliferation and related vascular diseases.
References
- 1. Humeres C et al.. 2024. Fibroblast Smad7 Induction Protects the Remodeling Pressure-Overloaded Heart.. Circ Res 135(3):453-469 PMID: 38899461
- 2. Bordan Z et al.. 2024. PDZ-Binding Kinase, a Novel Regulator of Vascular Remodeling in Pulmonary Arterial Hypertension.. Circulation 150(5):393-410 PMID: 38682326
- 3. Ferguson BS et al.. 2021. DUSP5-mediated inhibition of smooth muscle cell proliferation suppresses pulmonary hypertension and right ventricular hypertrophy.. Am J Physiol Heart Circ Physiol 321(2):H382-H389 PMID: 34142888
- 4. Dy DCM et al.. 2025. Functional analysis of TWIST1 domains regulating smooth muscle cell phenotype.. Front Cardiovasc Med 12:1659847 PMID: 41246007
- 5. Sala-Newby GB et al.. 2005. Regulation of vascular smooth muscle cell proliferation, migration and death by heparan sulfate 6-O-endosulfatase1.. FEBS Lett 579(28):6493-8 PMID: 16289059
- 6. Xu Y et al.. 2025. Autophagic degradation of SQSTM1 enables fibroblast activation to accelerate wound healing.. Autophagy 21(11):2401-2421 PMID: 40400126
- 7. Miglino N et al.. 2012. Calreticulin is a negative regulator of bronchial smooth muscle cell proliferation.. J Allergy (Cairo) 2012:783290 PMID: 22500186
- 8. Wen T et al.. 2023. miR-342-5p promotes vascular smooth muscle cell phenotypic transition through a negative-feedback regulation of Notch signaling via targeting FOXO3.. Life Sci 326:121828 PMID: 37270171
